Karuna Data Evaluating KarXT in Schizophrenia

 

• New efficacy, safety and tolerability analyses from the EMERGENT-3 trial support KarXT's potential as a new treatment option for schizophrenia
• Exploratory analysis will examine KarXT's impact on cognition in patients with schizophrenia in the EMERGENT-2 and EMERGENT-3 trials
• Company submitted New Drug Application (NDA) for KarXT, which includes data from the EMERGENT program, to the U.S. Food & Drug Administration (FDA) in September 2023

https://www.biospace.com/article/releases/karuna-therapeutics-to-present-data-from-the-emergent-program-evaluating-karxt-in-schizophrenia-at-the-36th-european-college-of-neuropsychopharmacology-ecnp-congress/